H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $80 from $73 and keeps a Buy rating on the shares post the Q2 report. The firm says Livmarli commercial momentum drove up the company’s 2025 revenue guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals Reports Strong Q2 2025 Growth
- Mirum Pharmaceuticals reports Q2 EPS (12c), consensus (33c)
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment
- Mirum Pharmaceuticals Advances Phase 3 Study on Maralixibat for Cholestatic Pruritus
- Mirum Pharmaceuticals price target raised to $76 from $68 at Evercore ISI